MedTrace Logo

Phosphorus Absorption in Healthy Adults and in Patients With Moderate Chronic Kidney Disease

NCT03108222 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2019-07-10

No results posted yet for this study

Summary

Chronic kidney disease (CKD) affects approximately 26 million Americans with many more at risk for disease development. Elevated serum phosphorus (P) and related abnormalities in P homeostasis due to progressive loss of kidney function are primary driving forces behind cardiovascular dysfunction and mortality in CKD patients. Intestinal P absorption is an critical aspect in P homeostasis but has been understudied, particularly in the early stages of CKD progression. This study aims to determine P absorption in patients with moderate CKD compared to healthy adults.

Conditions

  • Chronic Kidney Disease Mineral and Bone Disorder

Interventions

OTHER

Phosphorus Absorption Test

Subjects will undergo a radiophosphorus (P-33) absorption test over two days, that will include an oral administration of P-33 on the 1st day of the test, and an IV administration of P-33 on the 2nd day of the test. P-33 activity from serial serum and urine collections will be determined by scintillation counting, and fractional phosphorus absorption calculated by kinetic modeling.

Sponsors & Collaborators

  • Purdue University

    lead OTHER

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-25
Primary Completion
2019-08-30
Completion
2019-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03108222 on ClinicalTrials.gov